US20120330017A1 - Process for preparing oxymorphone, naltrexone, and buprenorphine - Google Patents
Process for preparing oxymorphone, naltrexone, and buprenorphine Download PDFInfo
- Publication number
- US20120330017A1 US20120330017A1 US13/601,327 US201213601327A US2012330017A1 US 20120330017 A1 US20120330017 A1 US 20120330017A1 US 201213601327 A US201213601327 A US 201213601327A US 2012330017 A1 US2012330017 A1 US 2012330017A1
- Authority
- US
- United States
- Prior art keywords
- oxymorphone
- salt
- alcohol
- mixture
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- WGCGSKTZLWEVFW-IOGNWATKSA-N [H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)C=CC2=O.[H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)CCC2=O.[H][C@]12OC3=C4C(=CC=C3O)C[C@@H]3C(=CC=C1OC)[C@@]42CCN3C Chemical compound [H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)C=CC2=O.[H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)CCC2=O.[H][C@]12OC3=C4C(=CC=C3O)C[C@@H]3C(=CC=C1OC)[C@@]42CCN3C WGCGSKTZLWEVFW-IOGNWATKSA-N 0.000 description 2
- LAIACFMYSCLEMG-KYZDLCPDSA-N [H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)CCC2=O.[H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)CCC2=O Chemical compound [H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)CCC2=O.[H][C@@]12OC3=C4C(=CC=C3O)C[C@H]3N(C)CC[C@]41[C@@]3(O)CCC2=O LAIACFMYSCLEMG-KYZDLCPDSA-N 0.000 description 2
- XQPJIXFIABJKTR-VCOBSJRSSA-N CN1CC[C@]23C4=C5C=CC(O)=C4O[C@H]2C(=O)C=C[C@@]3(O)[C@H]1C5.CN1CC[C@]23C4=C5C=CC(O)=C4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.COC1=CC=C2C3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@@]25CC[H]3C Chemical compound CN1CC[C@]23C4=C5C=CC(O)=C4O[C@H]2C(=O)C=C[C@@]3(O)[C@H]1C5.CN1CC[C@]23C4=C5C=CC(O)=C4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5.COC1=CC=C2C3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@@]25CC[H]3C XQPJIXFIABJKTR-VCOBSJRSSA-N 0.000 description 1
- FSJAFSSVDXQRTK-KRGOLBTHSA-N COC1=CC=C2[C@H]3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@@]25CCN3C.COC1=CC=C2[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@@]25CCN3.COC1=CC=C2[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@@]25CCN3C.COC1=CC=C2[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@@]25CCN3CC1CC1.O=C1C=C[C@@]2(O)[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@]52CCN3CC1CC1.O=C1CC[C@@]2(O)[C@H]3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@]52CCN3CC1CC1 Chemical compound COC1=CC=C2[C@H]3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@@]25CCN3C.COC1=CC=C2[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@@]25CCN3.COC1=CC=C2[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@@]25CCN3C.COC1=CC=C2[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@@]25CCN3CC1CC1.O=C1C=C[C@@]2(O)[C@H]3CC4=C5C(=C(OCC6=CC=CC=C6)C=C4)O[C@@H]1[C@]52CCN3CC1CC1.O=C1CC[C@@]2(O)[C@H]3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@]52CCN3CC1CC1 FSJAFSSVDXQRTK-KRGOLBTHSA-N 0.000 description 1
- WEJCPAUQABRUJJ-PRQUTZHMSA-N COC1=CC=C2[C@H]3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@@]25CCN3C.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1C.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1CC1CC1.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(O)C=C4)O[C@@H]2[C@]53CCN1C Chemical compound COC1=CC=C2[C@H]3CC4=C5C(=C(O)C=C4)O[C@@H]1[C@@]25CCN3C.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1C.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1CC1CC1.CO[C@]12C=C[C@@]3(C[C@@H]1C(C)=O)[C@H]1CC4=C5C(=C(O)C=C4)O[C@@H]2[C@]53CCN1C WEJCPAUQABRUJJ-PRQUTZHMSA-N 0.000 description 1
- UREFDLNWMZXBKO-RUXLVTQUSA-N CO[C@]12C=C[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1CC1CC1.CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(=C(O)C=C4)O[C@@H]2[C@]53CCN1CC1CC1 Chemical compound CO[C@]12C=C[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(=C(C)C=C4)O[C@@H]2[C@]53CCN1CC1CC1.CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(=C(O)C=C4)O[C@@H]2[C@]53CCN1CC1CC1 UREFDLNWMZXBKO-RUXLVTQUSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
- C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
- C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
Definitions
- This invention relates to preparation of opiates such as 14-hydroxymorphinone, oxymorphone, naltrexone, methylnaltrexone, buprenorphine, nalmefene, nalorphine, and naloxone from oripavine.
- Oxymorphone a potent opiate analgesic, is a semi-synthetic substitute for morphine. It is about ten times as potent as morphine. In the United States, FDA has approved oxymorphone hydrochloride in oral, parenteral and suppository forms. Naltrexone, methylnaltrexone, buprenorphine, nalmefene, nalorphine, and naloxone are other useful opiates.
- Oxymorphone can also be converted to these and other useful compounds, such as nal- compounds, including naloxone.
- Oxymorphone is typically synthesized using thebaine, morphine or another compound as a starting material.
- Thebaine when used, is generally obtained from the concentrated poppy straw (CSP-T), a poppy extract relatively rich in thebaine.
- Reaction schemes for producing oxymorphone from thebaine take several steps, to intermediates such as oxycodone, then conversion of the 3-methoxy group of oxycodone to the 3-hydroxy group of oxymorphone.
- U.S. Pat. No. 6,291,675 discloses a method for O-demethylation of the 3-methoxy group of opiates by use of a lithium hydride compound, providing a yield of O-demethylated opioid of at least 23%.
- U.S. Pat. No. 5,922,876 discloses preparation of oxymorphone from morphine. The process includes protection of the 3-hydroxy group of morphine with an aceto or benzyl group.
- Naltrexone is a narcotic antagonist; it also has been used to treat opioid abuse and alcoholic abuse. It can be prepared from thebaine (U.S. Pat. No. 3,332,950) or morphine (U.S. Pat. No. 6,013,796). Buprenorphine is a narcotic agonist/antagonist; it has been used for the treatment of opioid abuse. It can be prepared from thebaine (U.S. Pat. No. 3,433,791).
- a reference to a compound or component includes the compound or component by itself, as well as in combination with other compounds or components, such as mixtures of compounds.
- oripavine can be economically converted to other opiates, such as oxymorphone, naltrexone, and buprenorphine and derivatives thereof.
- Any starting material comprising oripavine may be used.
- the starting material preferably comprises greater than about 50% by weight oripavine, preferably greater than about 70%, more preferably greater than about 95%.
- the starting material is preferably purified oripavine, or a concentrate of poppy straw comprising oripavine as the main alkaloid (hereinafter, “CPS-O”).
- the oripavine comprises “natural oripavine,” but can comprise oripavine from any source.
- naturally oripavine is meant oripavine obtained from a natural source (e.g., botanical, bioengineered bacterial, etc.), and is meant to distinguish from oripavine obtained in a laboratory or factory setting by partial or total chemical synthesis, e.g., synthetic or semi-synthetic oripavine.
- Natural oripavine includes, without limitation, CPS-O, and purified oripavine obtained from CPS-O or other poppy straw.
- oripavine is oxidized with an oxidizing agent to obtain 14-hydroxymorphinone.
- the 14-hydroxymorphinone is then preferably reduced with a reducing agent to obtain oxymorphone.
- the 14-hydroxymorphinone can also be used in other ways, preferably to prepare other products.
- the oxidizing agent can comprise any oxidizing agent that permits the conversion of oripavine to 14-hydroxymorphinone, including, but not limited to, peroxy acids, such as performic acid, peracetic acid, and m-chloroperoxybenzoic acid (MCPBA). Mixtures of oxidizing agents may be used. When a peroxy acid is used, it may be added, or prepared in situ.
- peroxy acids such as performic acid, peracetic acid, and m-chloroperoxybenzoic acid (MCPBA).
- MCPBA m-chloroperoxybenzoic acid
- the oxidizing agent comprises a peroxy acid prepared in situ, it may be prepared in any manner, preferably by combining a peroxide and an acid.
- Any peroxide or combination of peroxides that can provide a peroxy acid can be used, preferably hydrogen peroxide, for example, aqueous hydrogen peroxide.
- Any acid or combination of acids that can provide a peroxy acid can be used, preferably formic acid, or acetic acid, for example, aqueous solutions of formic and/or acetic acid.
- Performic acid may be obtained, for example, by combining hydrogen peroxide and formic acid, and peracetic acid may be obtained by combining hydrogen peroxide with acetic acid.
- the reaction may be carried out in any appropriate solvent, preferably an aqueous solvent.
- a solvent comprising the corresponding acid.
- the oxidizing agent comprises performic acid, it is preferred to use a solvent comprising formic acid, and when the oxidizing agent comprises peracetic acid, it is preferred to use a solvent comprising acetic acid.
- MCPBA it is preferred to use a solvent comprising acetic acid.
- An exemplary process using performic acid as oxidizing agent is:
- An exemplary process using MCPBA as oxidizing agent is:
- reactions employing performic acid for example are preferably run in the range of about 20 to 60° C., more preferably about 40-50° C., even more preferably at about 50° C.
- reactions employing MCPBA are preferably run in the range of about 0 to 40° C., more preferably about 10-30° C., even more preferably at about ambient temperature, e.g., about 25° C.
- the reaction is run under conditions to convert oripavine to 14-hydroxymorphinone.
- at least about 90% of the oripavine is converted to 14-hydroxymorphinone, more preferably, about 95%, even more preferably about 98% or 99%.
- the conversion of oripavine to 14-hydroxymorphinone will be about 100%.
- the remaining amount of oripavine in the reaction mixture, as well as the amount of 14-hydroxymorphinone produced, can be determined by any method, such as by TLC or HPLC.
- Any reducing agent may be used to convert 14-hydroxymorphinone to oxymorphone.
- Catalytic hydrogenation is a preferred method, e.g., with a palladium catalyst, preferably palladium, or palladium hydroxide, on activated carbon (e.g., Pd/C).
- Catalytic hydrogenation may be performed at any suitable pressure, and is preferably done completely, or in part, in a low pressure environment.
- Catalytic hydrogenation preferably includes hydrogenation at or greater than, about 1 atmosphere pressure.
- low pressure is preferably meant less than about 10 atm, or less than about 4 atm.
- Catalytic hydrogenation reactions therefore, include hydrogenation at, e.g., at about 1-10 or about 1-4 atm.
- Low pressure hydrogenation generally requires less expensive processing and/or lower equipment costs than hydrogenation at higher pressures.
- the oxidizing and reduction may be performed as a “one pot” process, or may be done in separate vessels.
- the 14-hydroxymorphinone may be isolated, but need not be isolated, prior to reduction. In a preferred embodiment, the 14-hydroxymorphinone is not isolated in solid form prior to reduction.
- the opiate e.g., oxymorphone, or a salt thereof
- the opiate is purified.
- crude oxymorphone is isolated, purified, and converted to a salt, preferably the hydrochloride salt.
- An exemplary process for purifying crude oripavine base is:
- Purification aids may be used in the purification process.
- Preferred purification aids include adsorbents.
- Some preferred purification aids include activated carbon (commercially available as, e.g., DARCO), and/or powdered cellulose (commercially available as, e.g., SOLKA-FLOC).
- the reducing agent sodium bisulfite may be used, e.g., when performing the reaction in the presence of oxidants, e.g., under an oxidizing atmosphere. When the reaction is run under a non-oxidizing atmosphere, e.g., nitrogen gas, it may be possible to omit sodium bisulfite.
- purification aids including purification aids known in the art, may be selected and used by a person of ordinary skill in the art.
- Purified oxymorphone containing very little 14-hydroxymorphinone, is especially desirable because the impurity (14-hydroxymorphinone) is an alpha-beta-unsaturated ketone, which may be a carcinogen.
- Opiate salts e.g. of oxymorphone
- the hydrochloride is a preferred salt. Methods for preparing salts of compounds are known in the art. An exemplary process for preparing the hydrochloride salt of purified oxymorphone is:
- oxymorphone preferably purified oxymorphone
- a liquid preferably an alcohol and/or water; and more preferably ethanol, 2-propanol, combinations thereof, and combinations with water.
- an acid such as hydrochloric acid (preferably concentrated or gaseous HCl)
- hydrochloric acid preferably concentrated or gaseous HCl
- Oxymorphone can also be converted to other compounds, such as naloxone. Methods for effecting this conversion are known in the art.
- Oripavine can also be converted to naltrexone.
- the phenolic hydroxyl group in the 3-position of oripavine can be protected, for example by a benzyl group (or a substituted benzyl group, etc.) to 3-benzyl-oripavine, (1-1), followed by N-demethylation with a demethylation agent such as 1-chloroethyl chloroformate (ACE-Cl), and then reacting with methanol to obtain 3-benzyl-nororipavine, (1-2).
- a demethylation agent such as 1-chloroethyl chloroformate (ACE-Cl
- the nor-product is alkylated with (chloromethyl)cyclopropane (or other halomethylcyclopropane, or tosylmethylcyclopropane, for example) to give 3-benzyl-17-cyclopropylmethylnororipavine, (1-3).
- This is oxidized to 3-benzyl-17-cyclopropylmethyl-14-hydroxynororipavine, (1-4), by reacting with an oxidation agent such as a peroxy acid like peroxyformic acid, peroxyacetic acid, or MCPBA.
- the product which may or may not be isolated, can be hydrogenated to reduce the 7,8-double bond and to de-benzylate at the same time to give naltrexone, which can be converted to a salt.
- Oripavine can also be converted to buprenorphine.
- Scheme 2 One scheme for performing this conversion is shown in Scheme 2, below:
- oripavine can be reacted with methyl vinyl ketone under Diels Alder conditions to give 7 ⁇ -acetyl-6,7,8,14-tetrahydro-6,14-endoethenooripavine, (2-1), which can be protected for the 3-phenolic hydroxyl group by, for example, a benzyl group (or a substituted benzyl group, etc.) to 7 ⁇ -acetyl-3-benzyl-6,7,8,14-tetrahydro-6,14-endoethenooripavine, (2-2).
- a benzyl group or a substituted benzyl group, etc.
- This is de-methylated by reacting with a demethylating agent, such as ACE-Cl, and then refluxing in methanol to the nor product 7 ⁇ -acetyl-3-benzyl-6,7,8,14-tetrahydro-6,14-endoethenonororipavine, (2-3), which is alkylated with (chloromethyl)-cyclopropane (or other halomethylcyclopropane, or tosylmethylcyclopropane, for example) to 7 ⁇ -acetyl-3-benzyl-17-cyclopropylmethyl-6,7,8,14-tetrahydro-6,14-endoethenonororipavine, (2-4).
- a demethylating agent such as ACE-Cl
- oripavine is protected with a benzyl group first and then reacted with methyl vinyl ketone under Diels Alder conditions.
- Oxymorphone, naltrexone, or buprenorphine, or salts thereof, preferably HCl salts may be prepared into pharmaceutical dosage forms.
- Pharmaceutical dosage forms include, but are not limited to, tablets, pills, capsules (including hard or soft gelatin capsules), parenteral formulations, suppositories, patches, and powders.
- a salt e.g., the hydrochloride
- Oxymorphone base may be used, e.g., for transdermal patches.
- Preferred dosage forms include parenteral formulations and suppositories.
- Pharmaceutical dosage forms comprising, e.g., oxymorphone, naltrexone, or buprenorphine, may include one or more pharmaceutically acceptable excipients, and can be selected by those of ordinary skill in the art.
- Pharmaceutically acceptable excipients include, but are not limited to, carrier vehicles, stabilizing agents, solubilizing agents, lubricating agents, flow agents, bulking agents, control release agents, disintegating agents, binding agents, pigments, flavoring agents, and coating agents.
- Oripavine (50.0 g, 168 mmol), de-ionized water (70 ml), and 90% formic acid (42.0 g, 0.821 mol) were charged into a 500 ml 3-necked round bottom flask.
- the solution was stirred at 30-40° C. and to the composition was added 35% hydrogen peroxide, drop-wise (19.7 g, 0.203 mol), while keeping the temperature below 40° C.
- the mixture was stirred at 40-50° C. for 4 hours.
- the reaction mixture was transferred to a 1-L hydrogenation vessel and 5% Pd/C (3.2 g) and 2-propanol (160 ml) were added.
- Oripavine (50.0 g, 168 mmol), was converted to 14-hydroxymorphinone as in Example 2 through and including addition of hydrogen peroxide. Upon completion of the addition, the mixture was stirred at 40-50° C. By HPLC, it was determined that the area ratio of 14-hydroxymorphinone:oripavine is 27.2:72.8 after 1 hour, and 99.3:0.7 after 4 hours. After 4 hours 40 minutes, the reaction mixture was transferred to a 1-L hydrogenation vessel and 5% Pd/C (3.2 g) (Degussa E101 ofw, H 2 O 56.2%) was added. Hydrogenation proceeds at 46-52 psig at room temperature overnight (about 18 h). The mixture was filtered, and rinsed with about 50 ml water.
- a mixture of CPS-O (6.92 g contains 76% (5.26 g, 17.7 mmol) of oripavine), meta-chloroperoxybenzoic acid (MCPBA, 4.30 g) and glacial acetic acid (52 ml) is stirred at room temperature for 5 hours. The amount of oripavine is then expected to be not more than 1% by HPLC analysis. To the resulting 14-hydroxymorphinone mixture is added 5% Pd/C (0.55 g) and hydrogenation proceeds at room temperature at 48 psig of hydrogen for about 18 hours. The amount of unreacted 14-hydroxymorphinone is expected to be not more than 0.5% by HPLC analysis. The mixture is filtered to remove the catalyst and the filtrate is evaporated to almost dryness.
- Oxymorphone HCl meets the specifications in the USP 2006 monograph for Oxymorphone Hydrochloride.
- oripavine 28.7 g, 96.5 mmol
- 2-propanol 90 ml
- the mixture is cooled to 10° C. and the solids filtered off, washed with cold 2-propanol and dried at 50° C. to produce an anticipated yield of 32.9 g (93% yield) of 7 ⁇ -acetyl-6,7,8,14-tetrahydro-6,14-endo-ethenooripavine.
Abstract
Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included.
Description
- This application is a Continuation of U.S. patent application Ser. No. 13/013,569, filed Jan. 25, 2011, which is a Continuation of U.S. patent application Ser. No. 11/873,093, filed Oct. 16, 2007, which application claims priority to U.S. Provisional Application No. 60/829,817, filed Oct. 17, 2006, and to U.S. Provisional Application No. 61/007,897, for which a Request to Convert Non-Provisional application to Provisional application Under 37 C.F.R. §1.53(c)(2) was granted Dec. 20, 2007, from U.S. application Ser. No. 11/611,049, filed Dec. 14, 2006, the disclosures of each of which is incorporated herein by reference in its entirety.
- 1. Field of the Invention
- This invention relates to preparation of opiates such as 14-hydroxymorphinone, oxymorphone, naltrexone, methylnaltrexone, buprenorphine, nalmefene, nalorphine, and naloxone from oripavine.
- 2. Background of the Invention and Related Art
- Oxymorphone, a potent opiate analgesic, is a semi-synthetic substitute for morphine. It is about ten times as potent as morphine. In the United States, FDA has approved oxymorphone hydrochloride in oral, parenteral and suppository forms. Naltrexone, methylnaltrexone, buprenorphine, nalmefene, nalorphine, and naloxone are other useful opiates.
- Oxymorphone can also be converted to these and other useful compounds, such as nal- compounds, including naloxone.
- Oxymorphone is typically synthesized using thebaine, morphine or another compound as a starting material. Thebaine, when used, is generally obtained from the concentrated poppy straw (CSP-T), a poppy extract relatively rich in thebaine. Reaction schemes for producing oxymorphone from thebaine take several steps, to intermediates such as oxycodone, then conversion of the 3-methoxy group of oxycodone to the 3-hydroxy group of oxymorphone. U.S. Pat. No. 6,291,675, for example, discloses a method for O-demethylation of the 3-methoxy group of opiates by use of a lithium hydride compound, providing a yield of O-demethylated opioid of at least 23%. U.S. Pat. No. 5,922,876 discloses preparation of oxymorphone from morphine. The process includes protection of the 3-hydroxy group of morphine with an aceto or benzyl group.
- Naltrexone is a narcotic antagonist; it also has been used to treat opioid abuse and alcoholic abuse. It can be prepared from thebaine (U.S. Pat. No. 3,332,950) or morphine (U.S. Pat. No. 6,013,796). Buprenorphine is a narcotic agonist/antagonist; it has been used for the treatment of opioid abuse. It can be prepared from thebaine (U.S. Pat. No. 3,433,791).
- Features and advantages of the present invention will be set forth in the description of invention that follows, and will be apparent, in part, from the description or may be learned by practice of the invention. The invention will be realized and attained by the compositions, products, and methods particularly pointed out in the written description and claims hereof.
- Unless otherwise stated, a reference to a compound or component includes the compound or component by itself, as well as in combination with other compounds or components, such as mixtures of compounds.
- As used herein, the singular forms “a,” “an,” and “the” include the plural reference unless the context clearly dictates otherwise.
- Except where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not to be considered as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding conventions.
- Additionally, the recitation of numerical ranges within this specification is considered to be a disclosure of all numerical values and ranges within that range. For example, if a range is from about 1 to about 50, it is deemed to include, for example, 1, 7, 34, 46.1, 23.7, or any other value or range within the range.
- Unless otherwise noted, all reactions are run under inert conditions, such as under nitrogen or argon for safety and/or to avoid the formation of N-oxide by-products.
- The present inventor has discovered that oripavine can be economically converted to other opiates, such as oxymorphone, naltrexone, and buprenorphine and derivatives thereof. Any starting material comprising oripavine may be used. The starting material preferably comprises greater than about 50% by weight oripavine, preferably greater than about 70%, more preferably greater than about 95%. The starting material is preferably purified oripavine, or a concentrate of poppy straw comprising oripavine as the main alkaloid (hereinafter, “CPS-O”).
- Preferably, the oripavine comprises “natural oripavine,” but can comprise oripavine from any source. By “natural oripavine” is meant oripavine obtained from a natural source (e.g., botanical, bioengineered bacterial, etc.), and is meant to distinguish from oripavine obtained in a laboratory or factory setting by partial or total chemical synthesis, e.g., synthetic or semi-synthetic oripavine. Natural oripavine includes, without limitation, CPS-O, and purified oripavine obtained from CPS-O or other poppy straw.
- Preferably, oripavine is oxidized with an oxidizing agent to obtain 14-hydroxymorphinone. The 14-hydroxymorphinone is then preferably reduced with a reducing agent to obtain oxymorphone. The 14-hydroxymorphinone can also be used in other ways, preferably to prepare other products.
- The oxidizing agent can comprise any oxidizing agent that permits the conversion of oripavine to 14-hydroxymorphinone, including, but not limited to, peroxy acids, such as performic acid, peracetic acid, and m-chloroperoxybenzoic acid (MCPBA). Mixtures of oxidizing agents may be used. When a peroxy acid is used, it may be added, or prepared in situ.
- When the oxidizing agent comprises a peroxy acid prepared in situ, it may be prepared in any manner, preferably by combining a peroxide and an acid. Any peroxide or combination of peroxides that can provide a peroxy acid can be used, preferably hydrogen peroxide, for example, aqueous hydrogen peroxide. Any acid or combination of acids that can provide a peroxy acid can be used, preferably formic acid, or acetic acid, for example, aqueous solutions of formic and/or acetic acid. Performic acid may be obtained, for example, by combining hydrogen peroxide and formic acid, and peracetic acid may be obtained by combining hydrogen peroxide with acetic acid.
- The reaction may be carried out in any appropriate solvent, preferably an aqueous solvent. When the oxidizing agent includes a peroxy acid, it is preferred to use a solvent comprising the corresponding acid. For example, when the oxidizing agent comprises performic acid, it is preferred to use a solvent comprising formic acid, and when the oxidizing agent comprises peracetic acid, it is preferred to use a solvent comprising acetic acid. When MCPBA is used, it is preferred to use a solvent comprising acetic acid.
- An exemplary process using performic acid as oxidizing agent is:
- An exemplary process using MCPBA as oxidizing agent is:
- Any temperature that permits the reaction to proceed may be used. The temperature need not remain constant, and may vary during the reaction. Higher reaction temperatures speed up the reaction, but may increase formation of by-products. Different oxidation agents may run optimally at different temperatures. Reactions employing performic acid, for example are preferably run in the range of about 20 to 60° C., more preferably about 40-50° C., even more preferably at about 50° C. Reactions employing MCPBA are preferably run in the range of about 0 to 40° C., more preferably about 10-30° C., even more preferably at about ambient temperature, e.g., about 25° C.
- The reaction is run under conditions to convert oripavine to 14-hydroxymorphinone. Preferably, at least about 90% of the oripavine is converted to 14-hydroxymorphinone, more preferably, about 95%, even more preferably about 98% or 99%. Preferably, the conversion of oripavine to 14-hydroxymorphinone will be about 100%.
- The remaining amount of oripavine in the reaction mixture, as well as the amount of 14-hydroxymorphinone produced, can be determined by any method, such as by TLC or HPLC.
- Any reducing agent may be used to convert 14-hydroxymorphinone to oxymorphone. Catalytic hydrogenation is a preferred method, e.g., with a palladium catalyst, preferably palladium, or palladium hydroxide, on activated carbon (e.g., Pd/C).
- Catalytic hydrogenation may be performed at any suitable pressure, and is preferably done completely, or in part, in a low pressure environment. Catalytic hydrogenation preferably includes hydrogenation at or greater than, about 1 atmosphere pressure. By “low pressure” is preferably meant less than about 10 atm, or less than about 4 atm. Catalytic hydrogenation reactions, therefore, include hydrogenation at, e.g., at about 1-10 or about 1-4 atm. Low pressure hydrogenation generally requires less expensive processing and/or lower equipment costs than hydrogenation at higher pressures.
- The oxidizing and reduction may be performed as a “one pot” process, or may be done in separate vessels. The 14-hydroxymorphinone may be isolated, but need not be isolated, prior to reduction. In a preferred embodiment, the 14-hydroxymorphinone is not isolated in solid form prior to reduction.
- Preferably, the opiate, e.g., oxymorphone, or a salt thereof, is purified. Preferably, crude oxymorphone is isolated, purified, and converted to a salt, preferably the hydrochloride salt. An exemplary process for purifying crude oripavine base is:
- Purification aids may be used in the purification process. Preferred purification aids include adsorbents. Some preferred purification aids include activated carbon (commercially available as, e.g., DARCO), and/or powdered cellulose (commercially available as, e.g., SOLKA-FLOC). The reducing agent sodium bisulfite may be used, e.g., when performing the reaction in the presence of oxidants, e.g., under an oxidizing atmosphere. When the reaction is run under a non-oxidizing atmosphere, e.g., nitrogen gas, it may be possible to omit sodium bisulfite. Other purification aids, including purification aids known in the art, may be selected and used by a person of ordinary skill in the art. Purified oxymorphone, containing very little 14-hydroxymorphinone, is especially desirable because the impurity (14-hydroxymorphinone) is an alpha-beta-unsaturated ketone, which may be a carcinogen.
- Opiate salts, e.g. of oxymorphone, may also be prepared. Any salt, preferably a therapeutically acceptable salt, may be included in the present invention. The hydrochloride is a preferred salt. Methods for preparing salts of compounds are known in the art. An exemplary process for preparing the hydrochloride salt of purified oxymorphone is:
- Generally, oxymorphone, preferably purified oxymorphone, is suspended or dissolved in a liquid, preferably an alcohol and/or water; and more preferably ethanol, 2-propanol, combinations thereof, and combinations with water. Then, an acid, such as hydrochloric acid (preferably concentrated or gaseous HCl), is added to the mixture at a higher temperature. After cooling for a period of time, preferably once the reaction is complete or substantially complete, the oxymorphone salt is separated from the mixture, washed, and dried.
- Oxymorphone can also be converted to other compounds, such as naloxone. Methods for effecting this conversion are known in the art.
- Oripavine can also be converted to naltrexone. One scheme for performing this conversion is shown in Scheme 1, below:
- Generally, the phenolic hydroxyl group in the 3-position of oripavine can be protected, for example by a benzyl group (or a substituted benzyl group, etc.) to 3-benzyl-oripavine, (1-1), followed by N-demethylation with a demethylation agent such as 1-chloroethyl chloroformate (ACE-Cl), and then reacting with methanol to obtain 3-benzyl-nororipavine, (1-2). The nor-product is alkylated with (chloromethyl)cyclopropane (or other halomethylcyclopropane, or tosylmethylcyclopropane, for example) to give 3-benzyl-17-cyclopropylmethylnororipavine, (1-3). This is oxidized to 3-benzyl-17-cyclopropylmethyl-14-hydroxynororipavine, (1-4), by reacting with an oxidation agent such as a peroxy acid like peroxyformic acid, peroxyacetic acid, or MCPBA. The product, which may or may not be isolated, can be hydrogenated to reduce the 7,8-double bond and to de-benzylate at the same time to give naltrexone, which can be converted to a salt.
- Oripavine can also be converted to buprenorphine. One scheme for performing this conversion is shown in Scheme 2, below:
- Generally, oripavine can be reacted with methyl vinyl ketone under Diels Alder conditions to give 7α-acetyl-6,7,8,14-tetrahydro-6,14-endoethenooripavine, (2-1), which can be protected for the 3-phenolic hydroxyl group by, for example, a benzyl group (or a substituted benzyl group, etc.) to 7α-acetyl-3-benzyl-6,7,8,14-tetrahydro-6,14-endoethenooripavine, (2-2). This is de-methylated by reacting with a demethylating agent, such as ACE-Cl, and then refluxing in methanol to the nor product 7α-acetyl-3-benzyl-6,7,8,14-tetrahydro-6,14-endoethenonororipavine, (2-3), which is alkylated with (chloromethyl)-cyclopropane (or other halomethylcyclopropane, or tosylmethylcyclopropane, for example) to 7α-acetyl-3-benzyl-17-cyclopropylmethyl-6,7,8,14-tetrahydro-6,14-endoethenonororipavine, (2-4). This is reacted with a Grignard reagent, tert-butyl magnesium chloride (or tert-butyl lithium), in THF to 3-benzyl-17-cyclopropylmethyl-6,14-endo-etheno-7α-(2-hydroxy-3,3-dimethyl-2-butyl)-6,7,8,14-tetrahydronororipavine, (2-5), which is reduced and de-benzylated at the same time by hydrogenation with Pd/C or Pd(OH)2 in hydrogen to buprenorphine, which can be converted to a salt.
- Alternatively, the hydroxyl group of oripavine is protected with a benzyl group first and then reacted with methyl vinyl ketone under Diels Alder conditions.
- Oxymorphone, naltrexone, or buprenorphine, or salts thereof, preferably HCl salts, may be prepared into pharmaceutical dosage forms. Pharmaceutical dosage forms include, but are not limited to, tablets, pills, capsules (including hard or soft gelatin capsules), parenteral formulations, suppositories, patches, and powders. Generally, a salt, e.g., the hydrochloride, is preferred. Oxymorphone base may be used, e.g., for transdermal patches. Preferred dosage forms include parenteral formulations and suppositories.
- Pharmaceutical dosage forms comprising, e.g., oxymorphone, naltrexone, or buprenorphine, may include one or more pharmaceutically acceptable excipients, and can be selected by those of ordinary skill in the art. Pharmaceutically acceptable excipients include, but are not limited to, carrier vehicles, stabilizing agents, solubilizing agents, lubricating agents, flow agents, bulking agents, control release agents, disintegating agents, binding agents, pigments, flavoring agents, and coating agents.
- To a stirred oripavine (166.7 mg; 0.561 mmol) solution in 0.5 mL 30% formic acid (4.185 mmol) was added 0.1 ml 30% hydrogen peroxide (0.979 mmol), and the resulting mixture was stirred at 50° C. After complete transformation as indicated by TLC, the reaction mixture was transferred to a Parr Shaker, and 5% Pd/C (51.9 mg) was added. The mixture was hydrogenated at room temperature under 28 inch-Hg overnight, filtered, basified with NH4OH, and extracted with methylene chloride (5×15 ml). The extract was evaporated under reduced pressure to give 113.4 mg of a pale yellow solid, yield 67.1%. The product has an identical retention time in HPLC and same Rf value in TLC to an oxymorphone standard.
- Oripavine (50.0 g, 168 mmol), de-ionized water (70 ml), and 90% formic acid (42.0 g, 0.821 mol) were charged into a 500 ml 3-necked round bottom flask. The solution was stirred at 30-40° C. and to the composition was added 35% hydrogen peroxide, drop-wise (19.7 g, 0.203 mol), while keeping the temperature below 40° C. Upon completion of the addition, the mixture was stirred at 40-50° C. for 4 hours. The reaction mixture was transferred to a 1-L hydrogenation vessel and 5% Pd/C (3.2 g) and 2-propanol (160 ml) were added. Hydrogenation proceeded at 46-52 psig at room temperature overnight (about 18 h). The catalyst in the mixture was filtered off. The filtrate and washings are combined and basified with 50% NaOH (59.6 g) to pH 9.16. The temperature was kept at below 30° C. during the basification. The slurry was stirred at room temperature for 1 hour, and filtered to give a brown solid, which was then dried at 90° C. and 25″ Hg vacuum overnight to provide the crude oxymorphone as light brown solids (48.2 g, 160 mmol, 95.2% yield).
- Oripavine (50.0 g, 168 mmol), was converted to 14-hydroxymorphinone as in Example 2 through and including addition of hydrogen peroxide. Upon completion of the addition, the mixture was stirred at 40-50° C. By HPLC, it was determined that the area ratio of 14-hydroxymorphinone:oripavine is 27.2:72.8 after 1 hour, and 99.3:0.7 after 4 hours. After 4 hours 40 minutes, the reaction mixture was transferred to a 1-L hydrogenation vessel and 5% Pd/C (3.2 g) (Degussa E101 ofw, H2O 56.2%) was added. Hydrogenation proceeds at 46-52 psig at room temperature overnight (about 18 h). The mixture was filtered, and rinsed with about 50 ml water. 250 ml of filtrate was obtained, to which was added 25 ml butanol, yielding a mixture having pH of 2.86. While kept at less than 30° C., or at about 19.6° C., the filtrate was basified with 57.5 g of 50% NaOH, resulting in a pH of 9.05. The mixture was stirred for about one hour at room temperature, filtered, washed with water (4×50 ml), yielding a brown solid. The wet cake was dried at 93° C. at 25″ Hg overnight, yielding 44.2 g, 87.2% yield, of oxymorphone as a light brown solid.
- A mixture of CPS-O (6.92 g contains 76% (5.26 g, 17.7 mmol) of oripavine), meta-chloroperoxybenzoic acid (MCPBA, 4.30 g) and glacial acetic acid (52 ml) is stirred at room temperature for 5 hours. The amount of oripavine is then expected to be not more than 1% by HPLC analysis. To the resulting 14-hydroxymorphinone mixture is added 5% Pd/C (0.55 g) and hydrogenation proceeds at room temperature at 48 psig of hydrogen for about 18 hours. The amount of unreacted 14-hydroxymorphinone is expected to be not more than 0.5% by HPLC analysis. The mixture is filtered to remove the catalyst and the filtrate is evaporated to almost dryness. The residue is dissolved in water and basified to pH 9 by ammonium hydroxide. The solids are collected by filtration and dried at 90° C. and under 25-inch Hg of vacuum for 3 hours to give crude oxymorphone (approximately 95% yield expected).
- A suspension of the crude oxymorphone (20.0 g, 66 mmol) and water (120 ml) was stirred at 45-55° C. Tartaric acid (5.5 g) was added to adjust the pH to 4.35 to complete dissolution. DARCO (1.0 g) and SOLKA-FLOC (1.0 g) were added and stirred at 45-55° C. for 1 hour. The mixture was filtered and rinsed with water (10 ml). The filtrate and washings were combined and to this were added DARCO (1.0 g), SOLKA-FLOC (1.0 g) and sodium bisulfite (0.4 g). The mixture was stirred for 1 hour at 45-55° C., filtered and rinsed with water (10 ml). 1-BuOH (12 ml) was added to the filtrate and stirred at 45-55° C. 50% NaOH (6.1 g) was added to adjust the pH to 8.56 at 45-55° C., in particular, 50.5° C. The slurry was cooled to room temperature and filtered. Light brown solids were collected and dried at 65° C. and 25″ Hg vacuum overnight to give purified oxymorphone (18.2 g, 60 m mol, 91.0% yield).
- Purified oxymorphone (17.8 g, 59 mmol) was suspended in 94% aq. ethanol (107 ml) and stirred at 50-60° C. Concentrated hydrochloric acid (32%) was added slowly to adjust the pH to 2.58. The mixture was allowed to cool to room temperature, and then cooled further to 0-10° C., stirred for 2 hours and filtered then washed with ethanol (3×20 ml). The isolated solids were dried at 75° C. under 25 inches-Hg overnight to give oxymorphone HCl as white solids (17.3 g, 51 mmol, 86.7% yield).
- This Oxymorphone HCl meets the specifications in the USP 2006 monograph for Oxymorphone Hydrochloride.
- A mixture of CPS-O (76% Oripavine, 13.16 g, 44 m mol), benzyl bromide (9.2 g) and potassium bicarbonate (17.6 g) in toluene (200 ml) is heated to reflux for 4 hours, then cooled and filtered. The filtrate is extracted with dilute acetic acid. Immediately, the extract is basified with ammonium hydroxide to collect 3-benzyloripavine (expected yield: 16.19 g; 95% yield).
- A solution of 3-benzyloripavine (11.62 g, 30 mmol), 1-chloroethyl chloroformate (5.52 g, 37.8 mmol) and proton sponge (1.1 g) in methylene chloride (80 ml) is heated at reflux for 2 hours. The reaction mixture is evaporated in vacuo to dryness. The residue is dissolved in methanol (50 ml), heated to reflux for 30 minutes, basified with ammonium hydroxide, and then evaporated to dryness. To the residue is added (chloromethyl)-cyclopropane (5.14 g, 55.6 m mol), sodium carbonate (14.7 g, 139 mmol), and potassium iodide (4.6 g, 28 mmol) in ethanol (250 ml) and heating proceeds at reflux for 20 hours. The mixture is cooled and evaporated in vacuo to dryness. The residue is basified with ammonium hydroxide and extracted with methylene chloride. The extract is washed with water, dried with anhydrous sodium sulfate, and evaporated in vacuo to dryness. The residue is chromatographed on silica gel with a eluting solvent system of methanol/ethyl acetate (10/90 v/v) to give 3-benzyl-17-cyclopropylmethylnororipavine (expected yield: 10.93 g; 85% yield).
- A mixture of 3-benzyl-17-cyclopropylmethylnororipavine (10 g, 23 mmol), formic acid (90%, 60 ml), D.I. water (3 ml), methanol (10 ml) and hydrogen peroxide (31%, 3.3 ml) is stirred and heated at 40-50° C. for 5 hours. The mixture is allowed to cool, then 5% Pd/C (0.5 g) is added, and the mixture is hydrogenated under 25-inch-Hg for 8 hours. The catalyst is filtered off. The residue is evaporated in vacuo to dryness to give a crude product, which is re-crystallized from acetone/water to give a white crystalline solid. It is dried at 90° C. under 25 inch-Hg of vacuum for 4 hours to give naltrexone (expected yield: 6.8 g; 86% yield). This product is identical to a USP standard of Naltrexone.
- A mixture of oripavine (28.7 g, 96.5 mmol) and methyl vinyl ketone (18 ml) in 2-propanol (90 ml) is stirred and heated at reflux for 6 hours. The mixture is cooled to 10° C. and the solids filtered off, washed with cold 2-propanol and dried at 50° C. to produce an anticipated yield of 32.9 g (93% yield) of 7α-acetyl-6,7,8,14-tetrahydro-6,14-endo-ethenooripavine.
- A mixture of 7α-acetyl-6,7,8,14-tetrahydro-6,14-endo-ethenooripavine (20.5 g, 55.8 m mol), benzyl bromide (11.5 g), and sodium carbonate (23.6 g) in toluene (350 ml) is heated at reflux for 4 hours. The reaction mixture is cooled and washed with water. The organic layer is evaporated in vacuo to dryness to give 7α-acetyl-3-benzyl-6,7,8,14-tetrahydro-6,14-endo-ethenooripavine (24.5 g, 96% yield).
- A solution of 7α-acetyl-3-benzyl-6,7,8,14-tetrahydro-6,14-endo-ethenooripavine (6.9 g, 15 m mol), 1-chloroethyl chloroformate (2.76 g, 19 m mol) and proton sponge (0.5 g) in methylene chloride (50 ml) is heated at reflux for 2 hours. The reaction mixture is evaporated in vacuo to dryness. The residue is dissolved in methanol (30 ml). To this is added a few drops of concentrated hydrochloric acid and heated to reflux for 30 minutes and basified with ammonium hydroxide. This is evaporated to dryness. To the residue is added (chloromethyl)-cyclopropane (2.07 g, 28 mmol), sodium carbonate (7.4 g, 64 mmol), and potassium iodide (2.3 g, 14 mmol) in ethanol (150 ml) and heated at reflux for 20 hours. The resulting mixture is cooled and evaporated in vacuo to dryness. The residue is basified with ammonium hydroxide and extracted with methylene chloride. The extract is washed with water, dried with anhydrous sodium sulfate and evaporated in vacuo to dryness. The residue is chromatographed on silica gel with a eluting solvent system of methanol/ethyl acetate (10/90 v/v) to give 7α-acetyl-3-benzyl-17-cyclopropylmethyl-6,7,8,14-tetrahydro-6,14-endo-ethenonororipavine (expected yield: 6.9 g; 92% yield).
- To 7α-acetyl-3-benzyl-17-cyclopropylmethyl-6,7,8,14-tetrahydro-6,14-endo-ethenonororipavine (6.6 g, 13 mmol) in dry THF (100 ml) is added tert-butyl magnesium chloride (2.0 M in THF, 8 ml, 16 mmol). The mixture was heated to reflux for 18 hours, cooled, THF (100 ml) is added and the mixture is quenched with saturated magnesium sulfate solution. The solution is separated from the semisolids and evaporated in vacuo to dryness to give 3-benzyl-17-cyclopropylmethyl-6,14-endo-etheno-7α-(2-hydroxy-3,3-dimethyl-2-butyl)-6,7,8,14-tetrahydronororipavine (expected yield: 7.5 g; 90% yield).
- A mixture of 3-benzyl-17-cyclopropylmethyl-6,14-endo-etheno-7α-(2-hydroxy-3,3-dimethyl-2-butyl)-6,7,8,14-tetrahydronororipavine (7.2 g, 13 m mol), glacial acetic acid (42 ml), and 5% Pd/C (0.36 g) is hydrogenated at 25 psig hydrogen pressure at 40° C. for 16 hours. The catalyst is filtered off and the filtrate evaporated in vacuo to dryness. The residue is re-crystallized from ethanol to give buprenorphine (expected yield: 52 g; 86% yield).
- To a solution of buprenorphine (5.1 g, 11 m mol) in ethanol (60 ml) at 50-60° C. is added concentrated hydrochloric acid to pH 2.5, the heating is maintained at 50-60° C. for 2 hours, and cooled to 10-15° C. The mixture is filtered to collect the solid. The solid is washed with cold ethanol and dried at 80° C. under 25 inch Hg of vacuum for 4 hours to give the final product (expected yield: 5.3 g; 96% Yield). This product is identical to a USP standard of Buprenorphine Hydrochloride.
- Although the present invention has been described in considerable detail with regard to certain versions thereof, other versions are possible, and alterations, permutations, and equivalents of the version shown will become apparent to those skilled in the art upon a reading of the specification and study of the drawings. Also, the various features of the versions herein can be combined in various ways to provide additional versions of the present invention. Furthermore, certain terminology has been used for the purposes of descriptive clarity, and not to limit the present invention. Therefore, any appended claims should not be limited to the description of the preferred versions contained herein and should include all such alterations, permutations, and equivalents as fall within the true spirit and scope of the present invention.
- Having now fully described this invention, it will be understood to those of ordinary skill in the art that the methods of the present invention can be carried out with a wide and equivalent range of conditions, formulations, and other parameters without departing from the scope of the invention or any embodiments thereof.
Claims (35)
1. A method of purifying oxymorphone comprising:
obtaining oxymorphone or a salt thereof, and
purifying the oxymorphone or a salt thereof such that the oxymorphone or a salt thereof is substantially free of impurities.
2. The method of claim 1 , wherein the purified oxymorphone or a salt thereof is substantially free of alpha-beta-unsaturated ketones.
3. The method of claim 1 , comprising adding tartaric acid to a mixture comprising the obtained oxymorphone or salt thereof.
4. The method of claim 1 , comprising mixing the obtained oxymorphone or salt thereof with sodium bisulfite.
5. The method of claim 1 , wherein the purification is facilitated by a purification aid.
6. The method of claim 5 , wherein the purification aid includes an adsorbent, activated carbon, powdered cellulose, tartaric acid, water, or sodium bisulfite.
7. The method of claim 1 , wherein the purification comprises heating the oxymorphone or a salt thereof in an acidic medium.
8. A method of preparing oxymorphone or a salt thereof substantially free of alpha-beta-unsaturated ketones, comprising oxidizing oripavine to obtain 14-hydroxymorphinone.
9. A method of preparing oxymorphone or a salt thereof substantially free of alpha-beta-unsaturated ketones, comprising reducing 14-hydroxymorphinone to obtain oxymorphone or a salt thereof.
10. The method of claim 9 , wherein the 14-hydroxymorphinone is present in a mixture and the mixture is heated in formic acid, and optionally water.
11. The method of claim 10 , wherein the mixture is heated in formic acid, water, and optionally alcohol.
12. The method of claim 11 , wherein the mixture is heated in formic acid, water, and optionally alcohol, optionally in the presence of a catalyst.
13. The method of claim 11 , wherein the mixture is heated in formic acid, water, and optionally alcohol, optionally in the presence of a catalyst and hydrogen.
14. A method of preparing a purified oxymorphone salt substantially free of alpha-beta-unsaturated ketones, comprising converting oxymorphone to an oxymorphone salt.
15. The method of claim 14 , wherein the oxymorphone salt is oxymorphone hydrochloride and meets the specifications in the USP 2006 monograph for oxymorphone hydrochloride.
16. The method of claim 14 , wherein the alpha-beta-unsaturated ketones comprise 14-hydroxymorphinone.
17. The method of claim 14 , wherein conversion of oxymorphone to an oxymorphone salt comprises preparing the oxymorphone in an alcohol or in a mixture of alcohols.
18. The method of claim 14 , wherein conversion of oxymorphone to an oxymorphone salt comprises preparing the oxymorphone in a mixture of water and alcohol.
19. The method of claim 17 , wherein the alcohol comprises isopropyl alcohol, methanol, ethanol, propanol, and/or butanol.
20. The method of claim 18 , wherein the alcohol comprises isopropyl alcohol, methanol, ethanol, propanol, and/or butanol.
21. A method for purifying an oxymorphone salt comprising heating the oxymorphone salt in an alcohol or in an alcohol mixture.
22. The method of claim 21 , wherein the alcohol is an aqueous alcohol.
23. The method of claim 21 , wherein the oxymorphone salt is oxymorphone hydrochloride.
24. The method of claim 21 , wherein the alcohol is isopropyl alcohol.
25. The method of claim 21 , wherein the oxymorphone salt is dried.
26. The method of claim 25 , wherein the oxymorphone salt is dried after heating in the alcohol or alcohol mixture.
27. A method for preparing a purified oxymorphone or oxymorphone salt substantially free of impurities, comprising
preparing oxymorphone or an oxymorphone salt in an alcohol, a mixture of alcohol and water, or a mixture of alcohols;
isolating the oxymorphone or oxymorphone salt; and
drying the oxymorphone or oxymorphone salt.
28. The method of claim 27 , wherein the preparation of the oxymorphone or oxymorphone salt in an alcohol, a mixture of alcohol and water, or a mixture of alcohols comprises heating the oxymorphone or oxymorphone salt.
29. The method of claim 28 , wherein the oxymorphone or oxymorphone salt is heated to 50-60° C.
30. The method of claim 28 , wherein the oxymorphone or oxymorphone salt is heated to reflux.
31. The method of claim 28 , wherein the oxymorphone or oxymorphone salt is heated in a mixture comprising formic acid, water, and optionally alcohol in the presence of a catalyst.
32. The method of claim 28 , wherein the oxymorphone or oxymorphone salt is heated in a mixture comprising formic acid, water, and optionally alcohol, optionally in the presence of a catalyst and hydrogen.
33. The method of claim 27 , wherein the alcohol comprises isopropyl alcohol, methanol, ethanol, propanol, and/or butanol.
34. The method of claim 27 , wherein the drying comprises applying vacuum and/or heat to the oxymorphone or oxymorphone salt.
35. A method of preparing oxymorphone or a salt thereof from oripavine, comprising purifying the oxymorphone or the salt thereof such that the oxymorphone or the salt thereof is substantially free of oripavine.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/601,327 US20120330017A1 (en) | 2006-10-17 | 2012-08-31 | Process for preparing oxymorphone, naltrexone, and buprenorphine |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82981706P | 2006-10-17 | 2006-10-17 | |
US789706P | 2006-12-14 | 2006-12-14 | |
US11/873,093 US20080125592A1 (en) | 2006-10-17 | 2007-10-16 | Process for preparing oxymorphone, naltrexone, and buprenorphine |
US13/013,569 US8357802B2 (en) | 2006-10-17 | 2011-01-25 | Process for preparing oxymorphone |
US13/601,327 US20120330017A1 (en) | 2006-10-17 | 2012-08-31 | Process for preparing oxymorphone, naltrexone, and buprenorphine |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/013,569 Continuation US8357802B2 (en) | 2006-10-17 | 2011-01-25 | Process for preparing oxymorphone |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120330017A1 true US20120330017A1 (en) | 2012-12-27 |
Family
ID=39464529
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/873,093 Abandoned US20080125592A1 (en) | 2006-10-17 | 2007-10-16 | Process for preparing oxymorphone, naltrexone, and buprenorphine |
US13/013,569 Active US8357802B2 (en) | 2006-10-17 | 2011-01-25 | Process for preparing oxymorphone |
US13/601,327 Abandoned US20120330017A1 (en) | 2006-10-17 | 2012-08-31 | Process for preparing oxymorphone, naltrexone, and buprenorphine |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/873,093 Abandoned US20080125592A1 (en) | 2006-10-17 | 2007-10-16 | Process for preparing oxymorphone, naltrexone, and buprenorphine |
US13/013,569 Active US8357802B2 (en) | 2006-10-17 | 2011-01-25 | Process for preparing oxymorphone |
Country Status (1)
Country | Link |
---|---|
US (3) | US20080125592A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100274019A1 (en) * | 2006-10-17 | 2010-10-28 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007313103C1 (en) * | 2006-10-17 | 2014-01-30 | Penick Corporation | Process for preparing oxymorphone |
US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
AU2010239059B2 (en) | 2009-04-24 | 2016-06-09 | Brock University | Processes for the preparation of morphinane and morphinone compounds |
ES2537610T3 (en) | 2010-06-11 | 2015-06-10 | Rhodes Technologies | Process for the N-desalkylation of tertiary amines |
CA2802295C (en) | 2010-06-11 | 2016-09-20 | Rhodes Technologies | Transition metal-catalyzed processes for the preparation of n-allyl compounds and use thereof |
US8563571B2 (en) | 2010-07-22 | 2013-10-22 | Noramco, Inc. | Crystalline forms of oxymorphone hydrochloride |
WO2012151669A1 (en) | 2011-05-06 | 2012-11-15 | Brock University | Process for the preparation of morphine analogs via metal catalyzed n-demethylation/functionalization and intramolecular group transfer |
MX2015008624A (en) * | 2012-12-31 | 2016-12-08 | Rhodes Tech | PROCESS FOR PREPARING 7ß-SUBSTITUTED 6a,14a -ETHENOMORPHINANS AND 7A-SUBSTITUTED 6a,14a-ETHANOMORPHINANS. |
AU2014298257B2 (en) | 2013-08-02 | 2016-11-10 | Macfarlan Smith Limited | Process for the preparation of oxymorphone |
US9701687B2 (en) | 2014-05-05 | 2017-07-11 | Noramco, Inc. | Process for the preparation of opioid compounds |
US9701688B2 (en) | 2014-05-05 | 2017-07-11 | Noramco, Inc. | Process for the preparation of opioid compounds |
EP3023427A1 (en) * | 2014-11-19 | 2016-05-25 | Siegfried AG | Improved method of manufacturing buprenorphine and analogues thereof from oripavine |
US10287296B2 (en) | 2015-10-12 | 2019-05-14 | Noramco, Inc. | Process for the preparation of (S)-2-((4R,4aS,6R,7R,7aR,12bS)-7,9-dimethoxy-1,2,3,4,5,6,7,7a-octahydro-4a,7-ethano-4,12-methanobenzofuro[3,2-e]isoquinolin-6-yl)-3,3-dimethylbutan-2-ol |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9479A (en) * | 1852-12-21 | Improvement in rakes to grain-harvesters | ||
US3474101A (en) * | 1960-09-05 | 1969-10-21 | Reckitt & Sons Ltd | Thebaine and oripavine derivatives |
US3332950A (en) * | 1963-03-23 | 1967-07-25 | Endo Lab | 14-hydroxydihydronormorphinone derivatives |
GB1317210A (en) * | 1970-12-11 | 1973-05-16 | Macarlan Smith Ltd | Reduction of thebaine |
IN156632B (en) | 1983-08-22 | 1985-09-21 | Unichem Lab Ltd | |
FR2636330B1 (en) * | 1988-09-13 | 1990-11-30 | Sanofi Sa | PROCESS FOR THE PREPARATION OF MORPHINANE DERIVATIVES |
PT95069B (en) | 1989-08-24 | 1997-10-31 | Searle & Co | PROCESS FOR THE PREPARATION OF (+) - ISOMERS OF DERIVATIVES OF ENDOETANO / ENDOETANOEPOXIMOFINANO, UTEIS AS ANTI-TUSTIC AGENTS |
DK0914097T3 (en) | 1996-03-12 | 2002-04-29 | Alza Corp | Composition and dosage form comprising opioid antagonist |
AU3075197A (en) * | 1996-05-21 | 1997-12-09 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Novel methods of o-demethylation and n-deprotection |
US6067749A (en) | 1996-07-11 | 2000-05-30 | Tasmanian Alkaloids Pty. Ltd. | Papaver somniferum strain with high concentration of thebaine and oripavine |
US5869669A (en) * | 1996-07-26 | 1999-02-09 | Penick Corporation | Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates |
WO1998043978A1 (en) | 1997-03-27 | 1998-10-08 | Toray Industries, Inc. | Morphinane derivatives and medicinal use thereof |
GB9713703D0 (en) * | 1997-06-30 | 1997-09-03 | Johnson Matthey Plc | Preparation of opiates |
US6177567B1 (en) | 1999-10-15 | 2001-01-23 | Boehringer Ingelheim Chemicals, Inc. | Method for preparing oxycodone |
AR031682A1 (en) | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | PHARMACEUTICAL COMPOSITIONS |
JP4659943B2 (en) | 2000-02-25 | 2011-03-30 | 帝三製薬株式会社 | Patch containing buprenorphine hydrochloride |
US7119100B2 (en) | 2001-09-14 | 2006-10-10 | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences, P.L.A. China | Oripavine derivatives and their uses as pharmaceuticals |
CN1233645C (en) | 2001-09-14 | 2005-12-28 | 中国人民解放军军事医学科学院毒物药物研究所 | Novel oripavine derivative and its medical use |
US6864370B1 (en) * | 2003-06-05 | 2005-03-08 | Zhaiwei Lin | Process for manufacturing oxycodone |
WO2005028483A1 (en) | 2003-09-22 | 2005-03-31 | Glaxosmithkline Australia Pty Ltd | Process for the synthesis of morphinane compounds and intermediates thereof |
US7875718B2 (en) * | 2003-09-22 | 2011-01-25 | Johnson Matthey Public Limited Company | Process for the synthesis of morphinane compounds and intermediates thereof |
TWI483944B (en) * | 2004-03-30 | 2015-05-11 | Euro Celtique Sa | Oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oral dosage form,and pharmaceutically acceptable package having less than 25 ppm 14-hydroxycodeinone |
WO2006005112A1 (en) | 2004-07-09 | 2006-01-19 | Tasmanian Alkaloids Pty Ltd | Process for the synthesis of hydromorphone |
GB0421149D0 (en) * | 2004-09-23 | 2004-10-27 | Johnson Matthey Plc | Preparation of oxycodone |
WO2006084389A1 (en) | 2005-02-11 | 2006-08-17 | Cilag Ltd. | Method for purifying noroxymorphone compounds |
CA2636271A1 (en) | 2006-01-05 | 2007-07-19 | Mallinckrodt Inc. | The use of oripavine as a starting material for buprenorphine |
US8871779B2 (en) * | 2006-03-02 | 2014-10-28 | Mallinckrodt Llc | Process for preparing morphinan-6-one products with low levels of α,β-unsaturated ketone compounds |
AU2007313103C1 (en) | 2006-10-17 | 2014-01-30 | Penick Corporation | Process for preparing oxymorphone |
US20080125592A1 (en) | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
CA2674915C (en) | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
GB0624880D0 (en) * | 2006-12-14 | 2007-01-24 | Johnson Matthey Plc | Improved method for making analgesics |
CA2681740A1 (en) | 2007-03-23 | 2008-10-02 | Mallinckrodt Inc. | Improved preparation of oxymorphone from oripavine |
EP2019105A1 (en) | 2007-07-19 | 2009-01-28 | Siegfried Ltd. | Process for the preparation of quaternary n-alkyl morphine or morphinane alkaloid derivatives |
DE102008016998A1 (en) | 2008-04-03 | 2009-10-08 | GÖPFERICH, Achim, Prof. Dr. | Slow soluble cross-linked matrices for the administration of protein drugs |
CA2738250C (en) | 2008-09-30 | 2018-08-14 | Mallinckrodt Inc. | Processes for increasing the yield of the hydrolysis of the 3-o-methyl and 17-n-nitrile group in the preparation of opiate alkaloid derivatives |
CA2738761C (en) | 2008-09-30 | 2019-10-29 | Mallinckrodt Inc. | Processes for the production of buprenorphine with reduced impurity formation |
ES2560877T3 (en) | 2008-09-30 | 2016-02-23 | Mallinckrodt Llc | Processes for the alkylation of norbuprenorphine with less impurity formation |
US20110269964A1 (en) | 2010-04-29 | 2011-11-03 | Mallinckrodt Inc. | N-Alkylation of Opiates |
-
2007
- 2007-10-16 US US11/873,093 patent/US20080125592A1/en not_active Abandoned
-
2011
- 2011-01-25 US US13/013,569 patent/US8357802B2/en active Active
-
2012
- 2012-08-31 US US13/601,327 patent/US20120330017A1/en not_active Abandoned
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100274019A1 (en) * | 2006-10-17 | 2010-10-28 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
US9108974B2 (en) | 2006-10-17 | 2015-08-18 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
US9487532B2 (en) | 2006-10-17 | 2016-11-08 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
Also Published As
Publication number | Publication date |
---|---|
US8357802B2 (en) | 2013-01-22 |
US20110118466A1 (en) | 2011-05-19 |
US20080125592A1 (en) | 2008-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9487532B2 (en) | Process for preparing oxymorphone, naltrexone, and buprenorphine | |
US8357802B2 (en) | Process for preparing oxymorphone | |
US8134002B2 (en) | Process for preparing oxymorphone | |
AU2009233315B2 (en) | An improved process for the preparation of morphinane analogues | |
WO2008070658A1 (en) | Process for preparing oxycodone having reduced levels of 14-hydroxycodeinone | |
WO2008070656A2 (en) | Process for reducing impurities in oxycodone base | |
EP1664061B1 (en) | Process for the synthesis of morphinane compounds and intermediates thereof | |
EP2328900B1 (en) | PROCESS FOR MAKING MORPHINAN-6 alpha-OLS | |
AU2012216358B2 (en) | Process For Preparing Oxymorphone, Naltrexone and Buprenorphine | |
EP3252055B1 (en) | Process for obtaining 3,14-diacetyloxymorphone from oripavine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |